The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?
Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
Hosted on MSN
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...
One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has DexCom (DXCM) been one of those stocks this year? A quick ...
But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom ...
We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device ...
Shares of DexCom recently soared after the company reported better-than-expected third-quarter results. DexCom markets constant blood-glucose monitors for diabetic patients, and its next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results